Moderna shares surged Wednesday after the company announced its experimental mRNA cancer vaccine passed a key trial test [1].
The result marks a potential shift in oncology, as the treatment could become a first-of-its-kind cancer therapy if it receives regulatory approval [1, 2].
Developed in partnership with Merck, the vaccine utilizes messenger RNA technology to target cancer cells [1, 3]. Initial trial data reported on Aug. 19 showed the treatment was effective in its testing phase [1, 2]. The announcement triggered an immediate reaction from investors, with Moderna shares increasing by more than 100% [1].
While the company has not released the full data set to the public, the positive trajectory of the trial suggests the mRNA platform may be viable for treating malignancies beyond the infectious diseases for which it was first known [1, 2]. The surge in stock price reflects market confidence in the scalability of this personalized medicine approach.
Moderna has focused heavily on expanding its pipeline since the global pandemic, positioning itself as a leader in genomic medicine [1, 3]. This latest milestone indicates that the company's collaboration with Merck is meeting critical benchmarks for efficacy [1].
Further testing will be required to determine the long-term success rates, and safety profiles of the vaccine before it can be administered to the general public [1, 2]. The company said the initial results are positive, though the treatment remains in the experimental stage [1].
“Moderna shares more than doubled after the announcement”
This development suggests that mRNA technology can be successfully pivoted from preventative vaccines to therapeutic treatments for cancer. If the results hold in larger trials, it could move oncology toward highly personalized medicine, where vaccines are tailored to the specific genetic mutations of a patient's tumor, potentially reducing the reliance on systemic chemotherapy.
